Adolescents and young adults with a severe inherited immunodeficiency disorder improved following treatment with novel gene therapy developed at St. Jude Children’s Research Hospital and at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The results of this study appear today in the journal Science Translational Medicine.
The study involved five males with X-linked severe combined immunodeficiency disease (SCID-X1), also known as “Bubble Boy” disease, who were all treated at NIAID. This inherited disorder involves a mutation in the IL2RG gene that affects males and occurs in 1 of every 50,000 to 100,000 live births, leaving them with little to no immune protection.
To view the multimedia release go to:
http://www.multivu.com/players/English/7808651-st-jude-gene-therapy-results/
In an effort to improve outcomes for patients with some of the deadliest childhood cancers, St. Jude Children’s Research Hospital scientists have created the world’s largest collection of pediatric solid tumor samples, drug-sensitivity data and related information and have made the resource available at no charge to the global scientific community.
St. Jude and the Howard Hughes Medical Institute collaborated to create the resource, known as the Childhood Solid Tumor Network. The work is reported today as an advance online publication in the scientific journal Nature.
“Survival rates for children with recurrent solid tumors have not improved significantly in more than 20 years and remain below 30 percent,” said corresponding author Michael Dyer, Ph.D., chair of the St. Jude Department of Developmental Neurobiology and a Howard Hughes Medical Institute investigator. “This research will change that by promoting scientific collaboration to leverage the efforts of researchers worldwide to advance understanding and ultimately treatment of pediatric solid tumors.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8121952-st-jude-childrens-childhood-solid-tumor-network/
In this video shanthala Avigna clinical research student talking about teaching, placement and excellent facility provided to students in all aspects to reach their goal.
Consumers who choose a 2017 TOP SAFETY PICK+ award winner shouldn’t have trouble seeing the road on nighttime drives. Good or acceptable ratings in the Insurance Institute for Highway Safety’s new headlight evaluations set the latest crop of qualifiers apart. Thirty-eight models earn the “plus” accolade, and 44 earn TOP SAFETY PICK.
IIHS toughened the criteria for TOP SAFETY PICK+ to reflect new headlight evaluations launched in 2016. The recognition program is meant to encourage manufacturers to offer state-of-the-art protection for people in crashes, along with features that help drivers avoid crashes in the first place. In addition to good or acceptable headlights, the latter includes automatic braking technology, which has been part of the criteria since 2015.
For both awards, models must earn good ratings in the Institute’s small overlap front, moderate overlap front, side, roof strength and head restraint tests, as well as an advanced or superior rating for front crash prevention with standard or optional autobrake. Headlights are factored in only for the top award.
Four out of eight small pickup trucks evaluated by the Insurance Institute for Highway Safety earn good ratings for occupant protection in all five IIHS crashworthiness evaluations, but the lack of an automatic emergency braking system and poor-rated headlights means these pickups fall short of qualifying for either of the Institute’s safety awards.
IIHS engineers evaluated two body styles of each pickup — crew cab and extended cab. Crew cabs have four full doors and two full rows of seating. Extended cabs have two full front doors, two smaller rear doors and compact second-row seats. The Institute tests the two most popular versions of pickups because their performance can vary by body style. The ratings in this round of evaluations apply to 2017 models.
